If you searched "fruzaqla buy online," you are looking for fruquintinib — an oral, targeted VEGFR inhibitor for previously treated metastatic colorectal cancer (mCRC). The medicine carries two brand names: Fruzaqla in the United States, where Takeda commercializes it under license, and Elunate (爱优特) in China, where it was first developed and approved. GLT supplies the Fruquintinib (Elunate) 5mg capsules, the China NMPA-approved presentation, at an indicative around $350 for a 5mg × 7-capsule pack.
What Is Fruquintinib (Fruzaqla / Elunate)?
Fruquintinib is a small-molecule, quinazoline-based kinase inhibitor that selectively blocks vascular endothelial growth factor receptors VEGFR-1, VEGFR-2 and VEGFR-3. By shutting down these receptors, it starves tumors of the new blood vessels they need to grow — an anti-angiogenesis approach rather than a directly cytotoxic chemotherapy. It is taken orally, once daily, and is fundamentally different from the infused fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy that mCRC patients receive earlier in treatment.
The drug is a landmark in Chinese pharmaceutical innovation. It was discovered and developed by HUTCHMED (Hutchison MediPharma), a Shanghai-based biopharma company, making it the first self-developed innovative anticancer drug born in China. In China it is commercialized in partnership with Eli Lilly under the brand Elunate (爱优特), approved by the NMPA in September 2018. In the United States it is sold as Fruzaqla by Takeda, which licensed global rights (outside China) and won FDA approval in November 2023 — the same molecule, two regional names.
Fruzaqla vs Elunate: One Drug, Two Brand Names
The Fruzaqla/Elunate distinction is a common source of confusion, so it is worth spelling out:
- Fruzaqla is the US brand name, marketed by Takeda under license from HUTCHMED, with FDA approval granted in 2023.
- Elunate (爱优特) is the China brand name, marketed by HUTCHMED in partnership with Eli Lilly, with NMPA approval granted in 2018.
- The active ingredient is identical — fruquintinib capsules in 1mg and 5mg strengths, with the same 5mg-once-daily, 21-days-on / 7-days-off regimen.
Whether the box reads Fruzaqla or Elunate, patients are receiving the same VEGFR-targeted therapy. The only practical difference is the regional label and the commercial partner behind it.
Approved Indication: Metastatic Colorectal Cancer
Fruquintinib is approved for a single, precisely defined indication: metastatic colorectal cancer (mCRC) in adults whose disease has already been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and — if RAS wild-type and medically appropriate — an anti-EGFR therapy. In other words, it is a later-line oral option for patients who have progressed through the standard backbone of mCRC treatment.
Two facts matter for anyone researching this medicine. First, fruquintinib works regardless of RAS mutation status — it does not require a specific biomarker, unlike anti-EGFR options that are reserved for RAS wild-type disease. Second, the FDA granted it accelerated approval in 2023, and China approved it through the priority review pathway in 2018, reflecting the high unmet need in heavily pretreated mCRC.
Dosing: 5mg Once Daily, 21 Days On / 7 Days Off
Fruquintinib comes as 1mg and 5mg hard gelatin capsules. The recommended dose is 5mg orally once daily, with or without food, for the first 21 days of each 28-day cycle — three weeks on, one week off — continued until disease progression or unacceptable toxicity. The capsule should be swallowed whole and taken at about the same time each day.
The 1mg capsule exists for dose adjustment rather than as a starting dose. If side effects require it, the dose is reduced — first to 4mg, then to 3mg daily — using the 1mg capsules. If a patient cannot tolerate 3mg daily, treatment is permanently stopped. Patients who miss a dose should not double up the next day, and patients who vomit after a dose should not take a replacement.
Efficacy: The FRESCO-2 Survival Data
The strength of the approval rests on the international FRESCO-2 trial, a randomized, double-blind, placebo-controlled study in heavily pretreated mCRC. Patients receiving fruquintinib plus best supportive care lived a median overall survival of 7.4 months, compared with 4.8 months for placebo plus best supportive care — a 2.6-month improvement. This survival benefit, in a population that had already exhausted the standard treatment backbone, is what made fruquintinib the first new targeted therapy for mCRC approved in nearly a decade in the US.
A China-Origin Drug Goes Global
Fruquintinib's path to market is worth understanding because it reverses the usual direction of drug development. Most oncology medicines are invented in the West and later licensed into China; fruquintinib was invented in Shanghai, approved first in China in 2018, and only later won US FDA approval in 2023 — a first for a China-developed innovative cancer drug. For international patients this has a practical consequence: the China market is the origin market, with the longest real-world experience and the most mature supply channels. That is one reason buyers who search "fruquintinib buy" often end up sourcing the China-approved Elunate presentation rather than the newer US-branded Fruzaqla, which may carry a higher list price through US pharmacy channels.
Safety: Hypertension and Other Key Warnings
Fruquintinib has no boxed warning, but it carries several important precautions typical of anti-angiogenic agents. Hypertension is the most common — it occurred in about half of treated patients in the mCRC trials, including grade 3–4 events — so blood pressure should be controlled before starting and monitored throughout treatment. Other key warnings include hemorrhagic events, infections, gastrointestinal perforation or fistula (which requires permanent discontinuation), hepatotoxicity with elevated liver enzymes, proteinuria, palmar-plantar erythrodysesthesia (hand-foot skin reaction), posterior reversible encephalopathy syndrome (PRES), impaired wound healing around surgery, and arterial thromboembolic events.
The most common adverse reactions — each occurring in roughly 20% or more of patients — are hypertension, hand-foot skin reaction, proteinuria, voice changes (dysphonia), abdominal pain, diarrhea, and fatigue. Liver function tests should be checked before treatment and periodically during it. Because therapy continues across repeated 28-day cycles, patients should also plan for regular monitoring visits and a reliable, uninterrupted supply of capsules.
Fruzaqla Price and Where to Buy Online
Price is usually the deciding factor for an oral mCRC therapy taken in repeated 28-day cycles. The US-branded Fruzaqla is distributed by Takeda, and list pricing is set through US pharmacy channels with patient-assistance programs available for eligible commercial-insurance patients. For international buyers sourcing the China-approved originator presentation, GLT lists the Fruquintinib (Elunate) capsules at an indicative around $350 for the 5mg × 7-capsule pack, with the 1mg × 21-capsule pack at around $200. Because a full 21-day on-treatment cycle uses 21 × 5mg capsules, buyers typically order three 7-capsule packs per cycle.
Because fruquintinib is a prescription oncology medicine, GLT follows an inquiry process rather than a self-service cart:
- Confirm the treatment plan and the 5mg once-daily regimen with your oncologist.
- Send your inquiry via WhatsApp or email with the strength and quantity you need.
- Our team verifies availability and batch details, then arranges dispatch with appropriate storage.
For a broader look at sourcing China-approved oncology medicines, see our guide to sourcing China-sourced oncology medicines, and browse our other buying guides for related targeted therapies.
Questions or ready to order? Contact us on WhatsApp +86 15234153837 or email [email protected].
Frequently Asked Questions
What is fruquintinib used for?
Fruquintinib treats metastatic colorectal cancer (mCRC) in adults who have already received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy plus an anti-VEGF therapy. It is a later-line oral VEGFR inhibitor.
Is Fruzaqla the same as Elunate?
Yes. Fruzaqla is the US brand name marketed by Takeda, and Elunate (爱优特) is the China brand name marketed by HUTCHMED with Eli Lilly. Both contain the same active ingredient, fruquintinib.
Who makes fruquintinib?
Fruquintinib was discovered and developed by HUTCHMED (Hutchison MediPharma) in Shanghai — China's first self-developed innovative anticancer drug. Takeda holds US/global rights outside China, and Eli Lilly partners on China commercialization.
What is the dose of fruquintinib?
The recommended dose is 5mg orally once daily for the first 21 days of each 28-day cycle, with or without food. The 1mg capsule is used for dose reductions to 4mg or 3mg daily if side effects require it.
Does fruquintinib work for RAS-mutant colorectal cancer?
Yes. Fruquintinib is approved for mCRC regardless of RAS mutation status, unlike anti-EGFR therapies that are limited to RAS wild-type disease. No biomarker test is required to select patients.
How much does fruquintinib cost?
GLT's indicative price for the China-sourced Elunate presentation is around $350 for a 5mg × 7-capsule pack. A full 21-day on-treatment cycle typically requires three packs. Contact us for a current quote.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Fruquintinib (Fruzaqla / Elunate / 爱优特) is a prescription oncology medicine; always consult a qualified oncologist about diagnosis, dosing, and treatment. Prices are indicative and subject to confirmation at inquiry.